Top ENT Treatments for Chronic Sinusitis in 2026

Summary

Chronic sinusitis is a common and persistent inflammatory condition of the sinus cavities lasting more than 12 weeks, affecting approximately 12–15% of adults worldwide and significantly impairing quality of life through symptoms such as nasal congestion, facial pain, and reduced olfactory function. Particularly prevalent in urban environments, the disease imposes substantial socioeconomic costs and presents ongoing challenges in diagnosis and management due to its complex and heterogeneous nature.
The treatment landscape for chronic sinusitis in 2026 has evolved considerably, integrating advances in pharmacologic, surgical, and biologic therapies. Traditional interventions, including intranasal and systemic corticosteroids and functional endoscopic sinus surgery (FESS), remain foundational but often provide only temporary symptom relief, with frequent recurrences necessitating repeat treatments. Minimally invasive surgical techniques such as balloon sinuplasty have gained prominence due to their reduced invasiveness and favorable recovery profiles, supported by technological innovations like image-guided navigation and robotic-assisted surgery that enhance procedural safety and precision.
Biologic therapies targeting type 2 inflammatory pathways, notably interleukins IL-4, IL-5, IL-13, and immunoglobulin E (IgE), represent a major breakthrough for patients with refractory chronic rhinosinusitis with nasal polyps (CRSwNP). Agents such as dupilumab, omalizumab, and mepolizumab have demonstrated efficacy in improving symptoms, reducing corticosteroid dependency, and decreasing the need for revision surgery, although their high cost, uncertain long-term effects, and lack of validated biomarkers for patient selection pose ongoing challenges. Aspirin desensitization therapy remains an option for aspirin-exacerbated respiratory disease (AERD), but many patients still require adjunctive biologic treatment.
Despite these advances, controversies persist regarding the optimal sequencing and integration of surgical, pharmacologic, and biologic treatments, as well as the need for robust comparative effectiveness research. Additionally, the limited understanding of chronic sinusitis endotypes and the absence of universally accepted biomarkers hinder the full realization of personalized treatment strategies. Ongoing research into immune mechanisms, biomarker development, and emerging technologies continues to shape the future of chronic sinusitis management.

Overview of Chronic Sinusitis

Chronic sinusitis is a persistent medical condition characterized by inflammation of the sinuses lasting for an extended period, often beyond 12 weeks. It affects approximately 12–15% of adults and is more than a mere stubborn stuffy nose; the condition can significantly interfere with breathing, sleep, productivity, and overall well-being. The disease is notably prevalent in urban environments such as New York City, where allergens, fluctuating weather conditions, and indoor air irritants contribute to year-round symptoms.
The impact of chronic sinusitis extends beyond physical discomfort, imposing a substantial burden on patients’ health-related quality of life (HRQoL) and carrying considerable socioeconomic costs. The condition affects between 25% and 30% of patients with chronic rhinosinusitis (CRS) and between 1% and 4% of the general population. Symptoms typically include persistent nasal congestion, ongoing nasal drainage, facial pain or pressure, and impaired olfactory function, which together contribute to a chronic and debilitating clinical course.
Advancements in understanding the immunological mechanisms underlying chronic sinusitis, especially chronic rhinosinusitis with nasal polyposis (CRSwNP), have led to the development of novel therapeutic approaches. These include biologic agents targeting type 2 immune effectors such as interleukins IL-4, IL-5, IL-13, and immunoglobulin E (IgE), offering new hope for patients with severe and refractory disease. Conventional treatments such as intranasal corticosteroids (INCS) and endoscopic sinus surgery (ESS) often provide only temporary relief and are associated with frequent symptom recurrence.

Diagnosis of Chronic Sinusitis

The diagnosis of chronic sinusitis involves a comprehensive clinical evaluation aimed at distinguishing it from acute sinus infections and other sinonasal disorders. Chronic sinusitis is characterized by persistent inflammation of the sinus cavities lasting more than 12 weeks, often leading to significant symptoms that affect 12–15% of adults. Accurate diagnosis is critical to guiding effective treatment and improving patient outcomes.
Initial diagnosis typically includes a detailed patient history and physical examination, focusing on symptom duration, severity, and patterns. Symptoms commonly reported include nasal congestion, facial pain or pressure, nasal discharge, and impaired sense of smell. Unlike acute sinusitis, which is usually viral and resolves within 10 days without antibiotics, chronic sinusitis requires further evaluation due to its prolonged course.
Imaging studies, particularly computed tomography (CT) scans of the sinuses, are frequently employed to assess the extent of sinus inflammation and to identify anatomical variations that may contribute to disease persistence. The Lund–Mackay scoring system is often used to quantify sinus opacification on CT images, providing a standardized method to assess disease severity; however, it may not always correlate directly with symptom severity.
Endoscopic examination of the nasal passages and sinus openings is another key diagnostic tool. Functional endoscopic sinus surgery (FESS) itself originated from diagnostic endoscopy and now serves both diagnostic and therapeutic roles. Advances in imaging and technology, such as augmented reality-enhanced navigation during endoscopy, are improving the precision of diagnosis and surgical planning.
Biomarker analysis and emerging diagnostic modalities are gaining importance in chronic rhinosinusitis, particularly for identifying inflammatory endotypes that may respond to biologic therapies. Machine learning techniques are being explored to predict treatment responses to biologics such as mepolizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), facilitating personalized treatment approaches.
Despite these advances, limitations remain in the diagnostic process. The relatively recent introduction of novel biologics has outpaced the availability of comprehensive comparative studies evaluating their clinical efficacy against established surgical interventions like FESS. Ongoing research continues to refine diagnostic criteria and optimize the integration of emerging technologies and biomarkers in clinical practice.

Treatment Approaches

Management of chronic sinusitis involves a combination of medical and surgical therapies tailored to disease severity, patient response, and underlying inflammatory endotypes. Treatment options range from pharmacologic interventions and biologic therapies to endoscopic sinus surgery (ESS) and aspirin desensitization therapy (ADAT).

Pharmacologic Management

Pharmacotherapy aims to eradicate infection, reduce morbidity, and prevent complications associated with chronic sinusitis. Antibiotics remain a cornerstone in bacterial cases, though their optimal duration is not well established. An initial 2- to 4-week course may be reasonable, with some cases requiring prolonged treatment up to 12 months. However, following uncomplicated surgical management, the benefit of antibiotics is less clear. Selection of antibiotics depends on infection type, patient health status, and local resistance patterns. Common first-line agents include azithromycin, clarithromycin, or doxycycline, while more serious infections may require levofloxacin or amoxicillin/clavulanate. Due to concerns over fluoroquinolone-associated adverse effects, such as joint pain, their use is discouraged when alternatives are available.
Corticosteroids—both systemic and topical—are widely used to control inflammation. Systemic corticosteroids reduce polyp size, improve mucosal function, and enhance sinus drainage, often resulting in rapid symptom improvement, although effects are usually transient. Intranasal corticosteroids (INCS), delivered via sprays, rinses, drops, or advanced delivery systems, serve as first-line anti-inflammatory agents. Short courses of oral steroids are recommended for severe cases or rapid symptom relief. Special caution is advised in populations such as children, pregnant women, elderly patients, and those with comorbid asthma due to cumulative steroid exposure.

Surgical Interventions

Endoscopic sinus surgery (ESS) remains a vital option when medical therapy fails to provide adequate symptom control. Technological advancements, including image-guided navigation, high-definition visualization, and robotic-assisted techniques, have enhanced the precision and safety of ESS, leading to improved outcomes, reduced complications, and faster recovery. Despite surgical intervention, a subset of patients experiences recurrent symptoms, necessitating adjunctive or alternative therapies.

Biologic Therapies

Biologic agents have emerged as promising treatments, particularly for chronic rhinosinusitis with nasal polyps (CRSwNP) and refractory cases. These therapies target specific inflammatory pathways involved in disease pathophysiology, such as type 2 immune effectors including interleukins IL-4, IL-5, IL-13, and IgE. Four biologics—dupilumab, omalizumab, mepolizumab, and stapokibart (approved in China)—have received approval for CRSwNP, with additional agents in development targeting Th1 and Th17 pathways.
Dupilumab has demonstrated consistent benefits in aspirin-exacerbated respiratory disease (AERD), improving upper and lower airway symptoms, olfactory function, and quality of life, even in patients who have failed aspirin desensitization therapy. Comparisons between biologics remain limited due to a lack of head-to-head studies. Common adverse effects include injection site reactions and headaches, while serious hypersensitivity reactions are rare but potentially life-threatening.
While biologics offer advantages such as reduced need for systemic corticosteroids and decreased frequency of revision surgeries, challenges remain. These include high costs, uncertain optimal treatment duration, absence of validated biomarkers to guide patient selection, and unclear positioning relative to ESS. Emerging therapies targeting novel inflammatory mediators such as thymic stromal lymphopoietin (TSLP) and IL-33 hold promise for expanding treatment options.

Aspirin Desensitization Therapy

Aspirin desensitization therapy (ADAT) is another option, particularly for patients with AERD. Although ADAT can be effective, a substantial proportion of patients remain symptomatic or are intolerant to the therapy, highlighting the need for alternative treatments such as biologics.

Innovations and Advances in 2026

In 2026, the treatment landscape for chronic sinusitis has undergone significant transformation due to technological and therapeutic advancements. Innovations in surgical techniques and targeted biologic therapies are offering more effective and personalized treatment options, improving outcomes for millions of patients.
One of the most notable advancements in sinus surgery is the increased adoption of minimally invasive procedures, such as endoscopic sinus surgery and balloon sinuplasty. Balloon sinuplasty, introduced in 2004, utilizes high-pressure, low-volume balloons to dilate blocked sinus ostia under endoscopic and fluoroscopic guidance, restoring natural sinus ventilation and drainage with reduced tissue trauma compared to traditional surgery. Over the past decade, endoscopic procedures have increased by more than 20%, reflecting a shift away from open surgeries towards less invasive methods that reduce complications and recovery times.
The integration of cutting-edge technologies like robotic-assisted surgery, image-guided navigation systems, and high-definition visualization tools has further enhanced surgical precision and safety. These advancements are especially prominent in complex ENT procedures, including skull base and transoral surgeries, enabling surgeons to better navigate anatomical structures and improve patient outcomes.
On the pharmacological front, targeted biologic therapies have emerged as a promising option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Four biologics—dupilumab, omalizumab, mepolizumab, and stapokibart (approved in China)—have been authorized to treat CRSwNP, offering improved quality of life, reduced reliance on systemic corticosteroids, and decreased need for endoscopic sinus surgery. These therapies work by modulating type 2 inflammatory pathways, allowing for more tailored treatment approaches based on patients’ inflammatory profiles.
Despite these advances, challenges remain in fully understanding the underlying pathophysiology of chronic sinusitis and establishing objective biomarkers to guide personalized treatment and assess outcomes. Nonetheless, the EUFOREA expert group has developed criteria to identify patients who are most likely to benefit from biologic agents, emphasizing factors such as evidence of type 2 inflammation, prior corticosteroid use, quality of life impairment, olfactory loss, and comorbid asthma.
Traditional treatments, including systemic and topical corticosteroids, continue to play a role in managing symptoms by reducing inflammation and improving mucosal function, though their effects may be transient and accompanied by side effects. Biological agents are currently viewed as complementary options for patients with uncontrolled disease or those unable to undergo surgery, rather than complete replacements for established therapies.

Comparative Effectiveness of Treatments

Management of chronic sinusitis involves a range of therapeutic options including pharmacologic interventions, surgical procedures, and emerging biologic therapies. Traditional treatments such as intranasal corticosteroids (INCS) and endoscopic sinus surgery (ESS) often provide only temporary relief, with frequent recurrence of symptoms, significantly impacting patients’ health-related quality of life (HRQoL). Systemic corticosteroids are effective in reducing inflammation, polyp size, and nasal obstruction, but their benefits are often transient and associated with potential side effects.
Among surgical approaches, functional endoscopic sinus surgery (FESS) has long been the standard. However, newer minimally invasive techniques such as balloon sinuplasty (also called balloon catheter sinusotomy) have gained popularity due to their reduced invasiveness and favorable recovery profiles. Balloon sinuplasty employs high-pressure, low-volume balloons to dilate occluded sinus ostia under endoscopic and fluoroscopic guidance, restoring natural sinus ventilation and drainage. Comparative studies indicate that balloon sinuplasty provides significantly lower postoperative sinonasal outcome test-20 (SNOT-20) scores, shorter operating times, and reduced complication rates compared to FESS, with no significant difference in revision surgery rates or radiologic outcomes measured by Lund–Mackay scores. These advantages translate to reduced hospital stays, fewer postoperative medications, and diminished need for follow-up visits.
Pharmacologic management also includes antibiotic therapy, although the optimal duration remains unclear. An initial 2- to 4-week course may be reasonable, with longer durations up to 12 months considered in certain cases. However, antibiotics show limited benefit following surgical management of uncomplicated chronic sinusitis and should be prescribed judiciously, especially given recent FDA warnings about fluoroquinolones and their side effects.
A promising advance in treatment is the advent of biologic therapies targeting type 2 immune effectors such as IL-4, IL-5, IL-13, and IgE. Dupilumab, an IL-4 receptor alpha antagonist, has demonstrated consistent benefits in aspirin-exacerbated respiratory disease (AERD) and severe refractory chronic rhinosinusitis with nasal polyps (CRSwNP), improving upper and lower airway symptoms, olfactory function, and overall quality of life, even among patients who failed aspirin desensitization therapy (ADAT). Compared to other biologics like omalizumab or anti–IL-5 agents, dupilumab appears to provide more consistent benefits, although direct comparative studies are lacking. Targeted biologic treatments offer the potential for personalized therapy tailored to individual inflammatory profiles, potentially reducing the need for multiple revision surgeries or long-term corticosteroid use. However, limitations remain due to an incomplete understanding of underlying pathophysiology and the absence of objective biomarkers to guide treatment selection and monitor outcomes.

Integration of Allergy Management and Immunotherapy

Allergy management plays a crucial role in the treatment of chronic rhinosinusitis (CRS), particularly in patients with underlying allergic rhinitis or type 2 inflammatory profiles. Traditional approaches, including allergen avoidance and intranasal corticosteroids, have formed the foundation of symptom control; however, these methods often provide only partial or temporary relief, especially in cases complicated by nasal polyps (CRSwNP). Advances in immunotherapy, especially allergen-specific immunotherapy (AIT), have demonstrated potential in modulating the immune response and reducing symptom severity over the long term.
The emergence of biologic therapies targeting key type 2 immune effectors such as interleukins IL-4, IL-5, IL-13, and immunoglobulin E (IgE) has revolutionized the management of CRS with nasal polyps. These targeted monoclonal antibodies, including dupilumab, have shown efficacy in controlling inflammation, reducing polyp size, and improving patients’ health-related quality of life (HRQoL). By addressing the

Biomarkers and Clinical Indicators in 2026

In 2026, significant advancements have been made in identifying biomarkers and clinical indicators to optimize treatment strategies for chronic rhinosinusitis with nasal polyps (CRSwNP). Machine learning techniques have been employed to define treatment response to biologics such as mepolizumab over extended periods, enabling more precise patient stratification based on clinical biomarkers. These approaches aim to enhance the prediction of therapeutic outcomes, thus tailoring interventions to individual inflammatory profiles.
The landscape of biologic therapies continues to expand, targeting various inflammatory pathways implicated in CRSwNP, including those associated with Th1 and Th17 immune responses. Several biologics currently under investigation address these pathways and have demonstrated efficacy in related inflammatory diseases such as eosinophilic asthma and atopic dermatitis. This cross-disease insight supports a more personalized approach to managing CRSwNP, allowing clinicians to select therapies that minimize the need for revision surgeries and reduce reliance on long-term corticosteroid use.
Despite these advances, challenges remain due to incomplete understanding of the complex pathophysiology underlying CRSwNP and the scarcity of robust, objective biomarkers correlating with disease severity and quality-of-life outcomes. Consequently, ongoing research is critical to identify reliable indicators that can inform clinical decision-making and improve patient-centered care.
Recent clinical data presented at the 2026 AAAAI Annual Meeting highlighted progress in biologic sequencing and immunotherapy strategies, emphasizing the integration of mechanistic insights into practical treatment algorithms. This includes the use of combination immunotherapies aimed at inducing durable tolerance and microbiome-based interventions to prevent atopic disease in high-risk populations. Collectively, these developments underscore the evolving role of biomarkers and clinical indicators in shaping personalized treatment paradigms for CRSwNP in 2026.

Guidelines and Recommendations

Current guidelines for the treatment of chronic sinusitis (CRS) in 2026 emphasize a tailored approach that integrates both surgical and medical therapies based on patient-specific factors. Functional endoscopic sinus surgery (FESS) remains a standard surgical option, demonstrating efficacy in improving sinonasal outcomes, as evidenced by meta-analyses comparing it to sinus balloon catheter dilation (SBCD). The latter has emerged as a minimally invasive alternative with comparable safety profiles and favorable outcomes on Lund–Mackay and sinonasal outcome test-20 (SNOT-20) scores, though further high-powered studies are warranted to consolidate these findings.
The choice between SBCD and FESS often depends on disease severity, anatomic considerations, and patient preference. Meta-analytic data support that both procedures exhibit low complication rates and similar revision surgery rates, with SBCD potentially offering shorter operating times. However, limitations in current evidence include relatively small sample sizes in randomized controlled trials and emerging novel biologics whose roles have yet to be fully defined through direct comparative studies with endoscopic surgery.
In addition to surgical options, contemporary management stresses the judicious use of antibiotics, with common agents including azithromycin, clarithromycin, and doxycycline recommended according to infection type and local resistance patterns. Fluoroquinolones are generally discouraged for less severe infections due to FDA warnings about adverse effects. The duration of antibiotic therapy is variable; initial courses of 2 to 4 weeks are typical, but some cases may require extended treatment up to 12 months, although the benefit of antibiotics post-surgery remains unclear.
Finally, emerging treatment paradigms are incorporating immunotherapy and biologics targeting specific inflammatory pathways in CRS, particularly for chronic rhinosinusitis with nasal polyps (CRSwNP). The 2026 AAAAI Annual Meeting highlighted advances in combination immunotherapies and microbiome-based prevention strategies, reflecting a shift toward precision medicine in otolaryngology. However, these novel therapies require further systematic evaluation to establish their safety and efficacy compared to established surgical interventions.

Future Directions and Research

The landscape of chronic sinusitis treatment in 2026 is marked by significant advancements and ongoing investigations that promise to further transform patient care. A key area of development involves biologic therapies, which have expanded the therapeutic arsenal beyond traditional corticosteroids and surgery. Currently, four biologics—dupilumab, omalizumab, mepolizumab, and stapokibart (approved in China but not by the US FDA)—are approved for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These agents have demonstrated the potential to improve quality of life, reduce systemic corticosteroid use, decrease the need for endoscopic sinus surgery (ESS), and better manage comorbidities. However, the evidence base remains limited by small sample sizes and the recent introduction of some biologics, such as stapokibart, highlighting the need for larger comparative studies to evaluate long-term safety and efficacy.
Beyond biologics, emerging minimally invasive procedures, including frontal sinus balloon sinuplasty, are being studied for their safety profiles and clinical outcomes. Initial data collected from a large US otolaryngology academy survey have begun to characterize complication rates and utilization patterns, laying the groundwork for more extensive global investigations. Meanwhile, technological innovations such as robotic-assisted and AI-driven sinus surgeries are in their nascent stages but hold promise for improving surgical accuracy and patient safety. These technologies currently serve primarily as adjuncts in surgical planning and execution, with rigorous safety protocols in place during their adoption phase.
Personalized medicine is also an important future direction. Understanding the heterogeneous inflammatory endotypes of chronic rhinosinusitis—beyond the Th2 pathway to include Th1 and Th17 mediated mechanisms—may enable more precise targeting of therapy with novel biologics currently under development. However, progress is impeded by a limited understanding of disease pathophysiology and the absence of objective biomarkers to guide treatment selection and monitor outcomes effectively.

The content is provided by Jordan Fields, Scopewires